CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Impact of Percutaneous Coronary Intervention for Chronic Total Occlusion in Non-Infarct-Related Arteries in Patients With Acute Myocardial Infarction (from the COREA-AMI Registry) Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing JACC Scientific Expert Panel A randomised trial comparing two stent sizing strategies in coronary bifurcation treatment with bioresorbable vascular scaffolds - The Absorb Bifurcation Coronary (ABC) trial Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment The EARLY Randomized Trial Intracoronary Optical Coherence Tomography-Derived Virtual Fractional Flow Reserve for the Assessment of Coronary Artery Disease Prevalence of Coronary Vasospasm Using Coronary Reactivity Testing in Patients With Spontaneous Coronary Artery Dissection The year in cardiovascular medicine 2020: interventional cardiology Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents Prognostic Value of the Residual SYNTAX Score After Functionally Complete Revascularization in ACS Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

Original Research2022 Feb, 79 (6) 562–573

JOURNAL:J Am Coll Cardiol. Article Link

A Score to Assess Mortality After Percutaneous Mitral Valve Repair

S Raposeiras-Roubin , M Adamo , X Freixa et al. Keywords: transcatheter edge-to-edge mitral valve repair; TEER; severe mitral regurgitation; risk stratification; risk predictor

ABSTRACT

BACKGROUND - Risk stratification for transcatheter edge-to-edge mitral valve repair (TEER) is paramount in the decision-making process for treating severe mitral regurgitation (MR).


OBJECTIVES - This study sought to create and validate a user-friendly score (MitraScore) to predict the risk of mortality in patients undergoing TEER.


METHODS - The derivation cohort was based on a multicentric international registry that included 1,119 patients referred for TEER between 2012 and 2020. Score discrimination was assessed using Harrells c-statistic, and the calibration was evaluated with the Gronnesby and Borgan goodness-of-fit test. An external validation was carried out in 725 patients from the GIOTTO registry.


RESULTS - After multivariate analysis, we identified 8 independent predictors of mortality during the follow-up (2.1 ± 1.8 years): age 75 years, anemia, glomerular filtrate rate <60 mL/min/1.73 m2, left ventricular ejection fraction <40%, peripheral artery disease, chronic obstructive pulmonary disease, high diuretic dose, and no therapy with renin-angiotensin system inhibitors. The MitraScore was derived by assigning 1 point to each independent predictor. The c-statistic was 0.70. Per each point of the MitraScore, the relative risk of mortality increased by 55% (HR: 1.55; 95% CI: 1.44-1.67; P < 0.001). The discrimination and calibration for mortality prediction was better than those of EuroSCORE II (c-statistic 0.61) or Society of Thoracic Surgeons score (c-statistic 0.57). The MitraScore maintained adequate performance in the validation cohort (c-statistic 0.66). The score was also predictive for heart failure rehospitalization and was correlated with the probability of clinical improvement.


CONCLUSIONS - The MitraScore is a simple prediction algorithm for the prediction of follow-up mortality in patients treated with TEER.